Company intelligence
BioLamina
Cell-specific culture matrices for improved cell functionality
About BioLamina
BioLamina is a biotechnology company with a scientific base and heritage in matrix biology and cell culture research. It supports scientists who have struggled for decades to grow pluripotent stem cells and other primary cells in the lab. By providing tools for efficient and easy cell culture, BioLamina aims to ease the path towards safe and effective cell therapies and make better cell assays and models for increasing accuracy in drug discovery and development. The power of Biolaminin® substrates, developed by BioLamina, has been demonstrated in numerous publications, and they will continue to provide vital support to the stem cell community, from scientific concepts to clinical studies.
Verified activity
Signals from BioLamina
3 published signals
Presence & Recognition
BioLamina colleague Elias Uhlin will attend the German Stem Cell Network (GSCN) Conference 2026 in Berlin representing the company.
Reported by BioLamina
Research & Knowledge
BioLamina published a study by Meyer et al. (2026) in which researchers cultured human renal proximal tubular epithelial cells on Biosilk 521—a recombinant spider silk membrane coated with Biolaminin 521 to mimic the kidney basement membrane.
Reported by BioLamina
Research & Knowledge
BioLamina published an application note titled Modelling the kidney in 2D and 3D exploring how full-length Biolaminin 521 and 511 support kidney research.
Reported by BioLamina